Key result
Intracoronary GP IIb/IIIa inhibitors support PCI for acute MI in COVID-19.
Why the study?
No targeted studies have been published on acute coronary syndrome or myocardial infarction in patients with COVID-19.
Describes a case of selective intracoronary administration of glycoprotein IIb/IIIa inhibitors during PCI in a patient with acute myocardial infarction and COVID-19.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in COVID-19 AMI; should not change practice without prospective validation.
До настоящего времени не опубликовано результатов целенаправленных исследований, посвященных острому коронарному синдрому или инфаркту миокарда у больных с COVID-19. В статье описано селективное интракоронарное введение ингибиторов IIb/IIIa гликопротеиновых рецепторов тромбоцитов при остром инфаркте миокарда у пациента с COVID-19 в ходе чрескожного коронарного вмешательства.
No takes yet. Share an insight, caveat, or question.
Коротких et al. (2022) studied this question. Selective intracoronary administration of glycoprotein IIb/IIIa inhibitors was reported during percutaneous coronary intervention for acute myocardial infarction in a patient with COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: